Skip Navigation


European Heart Journal Advance Access originally published online on August 9, 2006
European Heart Journal 2006 27(18):2147-2149; doi:10.1093/eurheartj/ehl170
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/18/2147    most recent
ehl170v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Desmet, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Desmet, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Delayed neointimal healing after drug-eluting stent implantation: seeing is believing

Walter Desmet

Department of Cardiology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium

Corresponding author. Tel: +32 16 344 235. E-mail address: walter.desmet@uz.kuleuven.ac.be

This editorial refers to ‘Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation’{dagger} by Takano et al., on page 2189

The first 150 words of the full text of this article appear below.

Ever since its introduction in 1977, the long-term benefit of percutaneous coronary intervention has been limited by the phenomenon of restenosis, i.e. recurrence of significant stenosis at the site of intervention. Whereas, after plain balloon angioplasty, restenosis is for roughly two-thirds due to negative vessel wall remodelling, the late lumen loss after stent implantation is virtually exclusively caused by neointimal hyperplasia, a proliferation of smooth muscle cells with deposition of abundant extracellular matrix. Over the last years, a multitude of anti-proliferative drugs have been tested, several of which have been found effective in inhibiting this neointimal hyperplasia when locally delivered from a polymer-encapsulated stent. The two compounds with the largest clinical experience are paclitaxel and sirolimus, a cytostatic macrocyclic lactone with both anti-inflammatory and anti-proliferative properties.

Although the efficacy of these drug-eluting stents (DES) in preventing restenosis has been well established over the last years, recently, concerns have been raised . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation
Masamichi Takano, Takayoshi Ohba, Shigenobu Inami, Koji Seimiya, Shunta Sakai, and Kyoichi Mizuno
EHJ 2006 27: 2189-2195. [Abstract] [FREE Full Text]